Gri Bio Is A Clinical Stage Biopharmaceutical Company Focused On Fundamentally Changing The Way Inflammatoryfibrotic And Autoimmune Diseases Are Treatedgri Bio S Therapies Are Designed To Target The Activity Of Nkt Cellswhich Are Key Regulators Earlier In The Inflammatory Cascadeto Interrupt Disease Progression And Restore The Immune System To Homeostasisnkt Cells Are Innate Like T Cells That Share Properties Of Both Nk And T Cells And Are A Functional Link Between The Innate And Adaptive Immune Responsestype 1 Invariant Nktinktcells Play A Critical Role In Propagating The Injuryinflammatory Responseand Fibrosis Observed In Inflammatory And Fibrotic Indicationsgri Bio S Lead Programgri 0621Is An Inhibitor Of Inkt Cell Activity And Is Being Developed As A Novel Oral Therapeutic For The Treatment Of Idiopathic Pulmonary Fibrosisa Serious Disease With Significant Unmet Needthe Company Is Also Developing A Pipeline Of Novel Type 2 Nkt Agonists For The Treatment Of Systemic Lupus Erythematosusadditionallywith A Library Of Over 500 Proprietary Compoundsgri Bio Has The Ability To Fuel A Growing Pipeline
